CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 155 enrolled
Drug / intervention
K-757 120 mg BID and K-833 100 mg BID +2 moredrug
Likely dose
K-757 120 mg BID and K-833 100 mg BIDfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06019559
NCT06019559Phase 2Completed
CompareCT.gov

A Randomized, Placebo-Controlled, Double-Blind 13-Week Study to Evaluate the Safety, Tolerability, and Weight Loss Efficacy of K-757 Alone and in Combination With K-833 in Participants Who Are Obese

Kallyope Inc.·interventional·Posted Aug 31, 2023·Updated Feb 26, 2025

In Brief

A Phase 2 clinical trial evaluating K-757 120 mg BID and K-833 100 mg BID, K-757 120 mg BID and matching placebo to K-833, and 1 other intervention for Obesity. Completed, enrolled 155 participants across 22 sites.

Detailed Summary

This is a study to evaluate the safety and efficacy of K-757 alone and in combination with K-833 versus placebo in participants who are obese.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedAug 31, 2023
Enrollment StartSep 15, 2023
Primary CompletionFeb 7, 2024
Study CompletionFeb 19, 2024
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 2.8 years ago

Interventions

K-757 120 mg BID and K-833 100 mg BIDdrug

K-757 was titrated to the maintenance dose of 120 mg twice daily (BID) by Day 22. K-833 was initiated at 100 mg once daily in the morning (QAM) and was titrated to the maintenance dose of 100 mg BID on Day 8. Both administered orally.

K-757 120 mg BID and matching placebo to K-833drug

K-757 was titrated to the maintenance dose of 120 mg twice daily (BID) by Day 22. Both administered orally.

Matching placebo to K-757 and matching placebo to K-833drug

Both administered orally.